However, signal blockade by these HER2 and EGFR inhibitors induces compensatory responses in cancer cells, such as the overexpression and dimerization of other RTKs (e.g., HER3, MET), activating bypass pathways and ultimately leading to therapeutic resistance [97]. Here, ERBB2 is linked to cancer.